2021
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
Lebrun-Frénay C, Rollot F, Mondot L, Zephir H, Louapre C, Le Page E, Durand-Dubief F, Labauge P, Bensa C, Thouvenot E, Laplaud D, de Seze J, Ciron J, Bourre B, Cabre P, Casez O, Ruet A, Mathey G, Berger E, Moreau T, Al Khedr A, Derache N, Clavelou P, Guennoc AM, Créange A, Neau JP, Tourbah A, Camdessanché JP, Maarouf A, Callier C, Vermersch P, Kantarci O, Siva A, Azevedo C, Makhani N, Cohen M, Pelletier D, Okuda D, Vukusic S, Kantarci O, Siva A, Pelletier D, Okuda D, Azevedo C, Makhani N, Radji F, Morel N, Grosset-Jeannin D, Ungureanu A, Boyer L, Suchet L, Elias Z, Lebrun-Frénay C, Cohen M, Mondot L, Thouvenot E, Ciron J, Durand-Dubief F, Brochet B, Ruet A, Ouallet J, Defer G, Branger P, Derache N, Clavelou P, Taithe F, Alkhedr A, Fromont A, Moreau T, Tourbah A, Casez O, Berger E, Zephir H, Outteryck O, Vermersch P, Hautecoeur P, Androdias G, Ionescu I, Pelletier J, Audoin B, Maarouf A, Ayrignac X, Carra-Dalliere C, Labauge P, Debouverie M, Mathey G, Cabre P, Laplaud D, Wiertlevski S, Bresch S, Castelnovo G, Papeix C, Louapre C, Maillart E, Lubetzki C, Stankoff B, Fontaine B, Giannesini C, Heinzleff O, Créange A, Bourre B, Gout O, Guegen A, Bensa C, Le Page E, Michel L, Magy L, De Seze J, Collongues N, Leray E, Guennoc A, Biotti D, Camdessanché J, De Broucker T, Sehaki S, Devys-Meyer N, Bereau M, Cappe C, Kounkou K, Dumont E, Lescieux E, Protin A, Kane M, Boucher J, Petit J, Tabellah Kasonde I, De Vilmarrest A, Nicol M, Malbezin M, Olaiz J, Rigaud-Bully C, Casey R, Rollot F, Vukusic I, Debard N, Cotton F, Abdelalli A, Di Lelio B, Pinna F, Guillemin F, Ziegler A, Callier C, Zehrouni K, Hodel J, Wahab A, Zedet M, Fagniez O, Laage C, Pottier C, Slesari I, Sampaio M, Neau J, Rabois E, Castex C, Hebant B, Guillaume M, Vimont C, Muraz R, Le Port D, Henry C, Berthe C, Freitas N, Visneux V, Forestier M, Beltran S, Meunier G, Servan J, Pico F, Chatagner V. Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. JAMA Network Open 2021, 4: e2128271. PMID: 34633424, PMCID: PMC8506228, DOI: 10.1001/jamanetworkopen.2021.28271.Peer-Reviewed Original ResearchConceptsGadolinium-enhancing lesionsSpinal cord lesionsClinical eventsMultiple sclerosisRisk of conversionCord lesionsRisk factorsMRI scansPhase III clinical trialsMagnetic resonance imaging (MRI) scansEarly clinical diseaseFirst clinical eventDisease-modifying therapiesEarly clinical eventsSpinal cord involvementAge 37 yearsResonance imaging scansPotential treatment effectsMS careCohort studyCord involvementStudy entryTertiary centerClinical symptomsOligoclonal bands
2020
Radiologically Isolated Syndrome: 10‐Year Risk Estimate of a Clinical Event
Lebrun‐Frenay C, Kantarci O, Siva A, Sormani M, Pelletier D, Okuda D, Azevedo C, Amato M, Bensa C, Berger E, Brochet B, Ciron J, Cohen M, Inglese M, Keegan B, Labauge P, Laplaud D, Le Page E, Louapre C, Makhani N, Mathey G, Mondot L, Montalban X, Pelletier J, Seze J, deStefano N, Thouvenot E, Tintore M, Tutuncuoglu M, Uygunoglu U, Vermersch P, Weinshenker B, Zeydan B. Radiologically Isolated Syndrome: 10‐Year Risk Estimate of a Clinical Event. Annals Of Neurology 2020, 88: 407-417. PMID: 32500558, DOI: 10.1002/ana.25799.Peer-Reviewed Original ResearchConceptsFirst clinical eventSubsequent clinical eventsGadolinium-enhancing lesionsSpinal cord lesionsClinical eventsRIS subjectsCord lesionsIndependent predictorsMultivariate Cox regression modelMagnetic resonance imaging (MRI) characteristicsBaseline independent predictorsWorldwide cohort studiesPositive cerebrospinal fluidCox regression modelAnn NeurolIsolated SyndromeRIS diagnosisCohort studySymptom onsetMale sexMultiple sclerosisOligoclonal bandsInfratentorial lesionsMean ageClinical managementClinical Reasoning: A 16-year-old girl with ataxia, oscillopsia, and behavioral changes
Silverman A, Selvadurai C, Picard J, Gluck L, Fisayo A, Makhani N, Benitez V. Clinical Reasoning: A 16-year-old girl with ataxia, oscillopsia, and behavioral changes. Neurology 2020, 94: 10.1212/wnl.0000000000009297. PMID: 32234821, PMCID: PMC7282879, DOI: 10.1212/wnl.0000000000009297.Peer-Reviewed Original Research
2019
Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG
Waubant E, Banwell B, Wassmer E, Sormani M, Amato M, Hintzen R, Krupp L, Rostásy K, Tenembaum S, Chitnis T, Aaen G, Ben Adou E, Al-Roughani R, Alvarez V, Anagnostouli M, Anlar B, Armangue T, Arrambide G, Baroncini D, Bembeeva R, Benson L, Bizjak N, Blaschek A, Boyko A, Brenton J, Brück W, Klein da Costa B, Dive D, Elpers C, Filippi M, de Oliveira Fragomeni M, Havrdova E, Hemingway C, Kornek B, Deiva K, Lacy A, Liba Z, Lim M, Lotze T, Mah J, Makhani N, Mar S, McKay K, Menascu S, Moiola L, Mulero P, Ndiaye M, Neuteboom R, Ness J, Lobato de Oliveira E, Otallah S, Patti F, Albino da Paz J, Perez C, Pohl D, Ponsonby A, Rensel M, Rocca M, Rijke N, Rodriguez M, Rossman I, Sakuma H, Schreiner T, Schteinschnaider A, Sikes E, Simone I, Sweeney M, Tillema J, Troxell R, Verhelst H, Vilchez L, De Waele L, Weinstock-Guttman B, Wilbur C, Yann M, Yeh E, Zafeiriou D. Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG. Neurology 2019, 92: 10.1212/wnl.0000000000007572. PMID: 31043474, PMCID: PMC6556085, DOI: 10.1212/wnl.0000000000007572.Peer-Reviewed Original Research
2018
Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis
Aaen G, Waltz M, Vargas W, Makhani N, Ness J, Harris Y, Casper TC, Benson L, Candee M, Chitnis T, Gorman M, Graves J, Greenberg B, Lotze T, Mar S, Tillema JM, Rensel M, Rodriguez M, Rose J, Rubin J, Schreiner T, Waldman A, Weinstock-Guttman B, Belman A, Waubant E, Krupp L. Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. Journal Of Child Neurology 2018, 34: 148-152. PMID: 30556452, PMCID: PMC6579723, DOI: 10.1177/0883073818815041.Peer-Reviewed Original ResearchConceptsPediatric multiple sclerosisMultiple sclerosisEarly developmental milestonesPediatric Multiple Sclerosis CentersPediatric-onset multiple sclerosisMultiple sclerosis onsetMultiple Sclerosis CenterDevelopmental milestonesPediatric controlsDisease onsetHealthy controlsSclerosisAge 18Age 11ChildrenOnsetIndividualized education planFurther researchControl
2017
MRI findings of optic pathway involvement in Miller Fisher syndrome in 3 pediatric patients and a review of the literature
Malhotra A, Zhang M, Wu X, Jindal S, Durand D, Makhani N. MRI findings of optic pathway involvement in Miller Fisher syndrome in 3 pediatric patients and a review of the literature. Journal Of Clinical Neuroscience 2017, 39: 63-67. PMID: 28209311, DOI: 10.1016/j.jocn.2016.12.049.Peer-Reviewed Original ResearchConceptsMiller Fisher syndromeOptic pathway involvementGuillain-Barré syndromeCranial nerve enhancementPediatric patientsFisher syndromeNerve enhancementPathway involvementCranial nerve involvementNerve involvementAcute illnessDemyelinating conditionMRI findingsBrighton criteriaClinical manifestationsOptic pathwayCase reportCranial nervesBrain MRIPatientsSyndromeInvolvementFindingsNerveIllness
2016
Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study
Makhani N, Schreiner T. Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study. Pediatric Neurology 2016, 57: 101-104. PMID: 26996405, DOI: 10.1016/j.pediatrneurol.2016.01.010.Peer-Reviewed Original ResearchConceptsOral dimethyl fumarateMultiple sclerosisDimethyl fumarateSide effectsFirst-line injectable therapiesBrain magnetic resonance imagingAbnormal liver transaminasesDual-Center ExperienceUsual adult doseMonths of therapyNew T2 lesionsFirst-line therapyCommon side effectsMagnetic resonance imaging (MRI) parametersPediatric multiple sclerosisDual-center studyChildren 18 yearsFormal clinical trialsMagnetic resonance imagingLiver transaminasesDisability scoresLaboratory abnormalitiesOral medicationsRelapse rateRetrospective review
2015
Radiologically Isolated Syndrome in a Pediatric Patient
George IC, DeStefano K, Makhani N. Radiologically Isolated Syndrome in a Pediatric Patient. Pediatric Neurology 2015, 56: 86-87. PMID: 26724214, DOI: 10.1016/j.pediatrneurol.2015.10.013.Peer-Reviewed Original Research
2013
Glatiramer acetate–induced acute hepatotoxicity in an adolescent with MS
Makhani N, Ngan BY, Kamath BM, Yeh EA. Glatiramer acetate–induced acute hepatotoxicity in an adolescent with MS. Neurology 2013, 81: 850-852. PMID: 23884038, PMCID: PMC3908464, DOI: 10.1212/wnl.0b013e3182a2cc4a.Peer-Reviewed Original Research
2009
Cyclophosphamide therapy in pediatric multiple sclerosisSYMBOLSYMBOL
Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosisSYMBOLSYMBOL. Neurology 2009, 72: 2076-2082. PMID: 19439723, PMCID: PMC2923592, DOI: 10.1212/wnl.0b013e3181a8164c.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAge of OnsetChildCyclophosphamideDisease ProgressionDrug Administration ScheduleDrug ResistanceFemaleGlatiramer AcetateHumansImmunosuppression TherapyImmunosuppressive AgentsInterferon-betaMaleMitoxantroneMultiple SclerosisPeptidesRetrospective StudiesSecondary PreventionSex DistributionTreatment OutcomeConceptsMultiple sclerosisTreatment of childrenInduction therapyMaintenance therapyTreatment initiationDisability Status Scale scoreAggressive multiple sclerosisFirst-line therapyRetrospective chart reviewMajority of patientsStatus Scale scoreCyclophosphamide therapyChart reviewDisability scoresMost patientsMulticenter experienceMultiple relapsesRelapse ratePatient selectionTransient alopeciaBladder carcinomaTreatment administrationCyclophosphamideSide effectsScale score